SPTBN4 (Q9H254) variants and mutations
SPTBN4 (also known as Q9H254) is a human protein-coding gene encoding a spectrin beta chain, non-erythrocytic 4 protein. It stabilizes axonal membrane domains and organizes ion channels and cytoskeletal complexes at nodes of Ranvier and neuromuscular structures. Biallelic pathogenic variants cause a severe neurodevelopmental disorder with congenital hypotonia, neuropathy, deafness, and respiratory insufficiency. This analysis covers 3,489 SPTBN4 variants and mutations. Of these, 75% have computational variant effect predictions. Disease context includes neurodevelopmental disorder with hypotonia, neuropathy, and deafness, hereditary disease, and neurodegenerative disease. Example SPTBN4 variants include A2T, A2V, and A2A.
Variant analysis overview
- Gene: SPTBN4
- Protein: Q9H254
- UniProt accession: Q9H254
- Organism: Homo sapiens
- Variants analyzed: 3489
- Variant scope: all variants
- Completed: 2026-08-20
Variant and mutation evidence
- Variant composition: 3,300 unspecified-consequence records; 91 synonymous variants; 80 missense variants; 2 in-frame deletions; 8 stop-gained variants; 4 frameshift variants; 4 splice-region variants
- Prediction scores: 2,610 variants have prediction scores (75% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: neurodevelopmental disorder with hypotonia, neuropathy, and deafness, hereditary disease, neurodegenerative disease, deafness, essential tremor, hearing loss, autosomal recessive, autosomal dominant nonsyndromic hearing loss, Benign familial chorea, Global developmental delay, myoclonic epilepsy, Hypotonia, Flexion contracture.
Protein structure and variant hotspots
- Protein features: 3 domains.
- Structural context: 470 variants have structural context.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, Interaction Network Analysis, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable SPTBN4 variants
Examples include A2T, A2V, A2A, Q3H, Q3R, Q3Q, V4A, V4G. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- A2T (p.Ala2Thr), NCI-TCGA Cosmic COSV1001, cosmic curated COSV10015, Variant assessed as somatic; moderate impact.
- A2V (p.Ala2Val), rs139091351, cosmic curated COSV10015, ESP rs139091351, ExAC rs139091351, CADD 24.70, PolyPhen-2 0.96, Uncertain significance, Inborn genetic diseases
- A2A (p.Ala2Ala), rs780717203, gnomAD 19-40472627-G-A, CADD 2.38
- Q3H (p.Gln3His), cosmic curated COSV58946, ExAC rs747766613, TOPMed rs747766613, gnomAD rs747766613, CADD 18.10, PolyPhen-2 0.00
- Q3R (p.Gln3Arg), gnomAD 19-40472629-A-G, MetaLR 0.23, MetaSVM -0.68
- Q3Q (p.Gln3Gln), rs747766613, gnomAD 19-40472630-G-A, CADD 4.62
- V4A (p.Val4Ala), rs144020509, ClinGen CA9445220, ClinVar RCV002773297, ESP rs144020509, CADD 14.70, PolyPhen-2 0.01, Uncertain significance, Inborn genetic diseases
- V4G (p.Val4Gly), ESP rs144020509, ExAC rs144020509, TOPMed rs144020509, gnomAD rs144020509, Uncertain significance
- V4I (p.Val4Ile), ExAC rs769325922, gnomAD rs769325922, CADD 9.52, PolyPhen-2 0.00
- V4L (p.Val4Leu), ExAC rs769325922, gnomAD rs769325922
- P5T (p.Pro5Thr), gnomAD rs1443500687, CADD 22.20, PolyPhen-2 0.51
- P5S (p.Pro5Ser), gnomAD 19-40472634-C-T, MetaLR 0.22, MetaSVM -0.69
- P5L (p.Pro5Leu), gnomAD 19-40472635-C-T, MetaLR 0.46, MetaSVM -0.10
- P5P (p.Pro5Pro), gnomAD 19-40472636-A-G, CADD 10.60
- G6E (p.Gly6Glu), NCI-TCGA Cosmic COSV5894, cosmic curated COSV58943, Variant assessed as somatic; moderate impact.
- G6R (p.Gly6Arg), gnomAD 19-40472637-G-C, MetaLR 0.42, MetaSVM -0.08
- E7D (p.Glu7Asp), ExAC rs749068938, TOPMed rs749068938, gnomAD rs749068938, CADD 16.00, PolyPhen-2 0.62
- E7K (p.Glu7Lys), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- E7E (p.Glu7Glu), rs749068938, gnomAD 19-40472642-A-G, CADD 8.84
- V8E (p.Val8Glu), ExAC rs771031613, gnomAD rs771031613, CADD 24.10, PolyPhen-2 0.37
- D9G (p.Asp9Gly), rs774383165, ExAC rs774383165, gnomAD rs774383165, CADD 28.10, PolyPhen-2 0.97, Variant assessed as somatic; moderate impact.
- D9N (p.Asp9Asn), gnomAD rs1234034911, CADD 26.80, PolyPhen-2 0.97
- D9V (p.Asp9Val), ExAC rs774383165, gnomAD rs774383165, CADD 26.60, PolyPhen-2 0.99
- D9D (p.Asp9Asp), rs2079898117, gnomAD 19-40472648-C-T, CADD 10.10
- N10D (p.Asn10Asp), TOPMed rs1347390202, gnomAD rs1347390202, CADD 23.60, PolyPhen-2 0.11
- N10K (p.Asn10Lys), gnomAD rs2079898188, CADD 20.40, PolyPhen-2 0.11
- M11R (p.Met11Arg), ExAC rs767569058, TOPMed rs767569058
- M11V (p.Met11Val), ESP rs376008345, ExAC rs376008345, TOPMed rs376008345, gnomAD rs376008345, CADD 14.20, PolyPhen-2 0.04, Uncertain significance, Inborn genetic diseases
- M11T (p.Met11Thr), gnomAD 19-40472653-T-C, MetaLR 0.33, MetaSVM -0.33
- E12D (p.Glu12Asp), NCI-TCGA Cosmic COSV5894, cosmic curated COSV58948, Variant assessed as somatic; moderate impact.
- E12Q (p.Glu12Gln), Ensembl rs2079898293, CADD 25.20, PolyPhen-2 0.63
- E12E (p.Glu12Glu), rs1272342616, gnomAD 19-40472657-G-A, CADD 7.06
- G13C (p.Gly13Cys), cosmic curated COSV58953
- G13D (p.Gly13Asp), NCI-TCGA Cosmic COSV5895, cosmic curated COSV58956, CADD 23.20, PolyPhen-2 0.99, Variant assessed as somatic; moderate impact.
- G13R (p.Gly13Arg), TOPMed rs2079898364
- G13G (p.Gly13Gly), rs2079898395, gnomAD 19-40472660-C-T, CADD 7.77
- L14M (p.Leu14Met), TOPMed rs1438499588, gnomAD rs1438499588, CADD 14.90, PolyPhen-2 0.10
- L14Q (p.Leu14Gln), gnomAD 19-40472662-T-A, MetaLR 0.09, MetaSVM -0.86
- L14L (p.Leu14Leu), rs910610977, gnomAD 19-40472663-G-A, CADD 0.58
- P15L (p.Pro15Leu), 1000Genomes rs540058459, ExAC rs540058459, gnomAD rs540058459, CADD 12.80, PolyPhen-2 0.01
- P15T (p.Pro15Thr), gnomAD 19-40472664-C-A, MetaLR 0.20, MetaSVM -0.90
- P15S (p.Pro15Ser), gnomAD 19-40472664-C-T, MetaLR 0.28, MetaSVM -0.81
- P15R (p.Pro15Arg), gnomAD 19-40472665-C-G, MetaLR 0.26, MetaSVM -0.64
- A16D (p.Ala16Asp), ExAC rs761018188, gnomAD rs761018188
- A16T (p.Ala16Thr), gnomAD rs1239957764, CADD 12.00, PolyPhen-2 0.01
- P17L (p.Pro17Leu), NCI-TCGA Cosmic COSV5894, cosmic curated COSV58945, Variant assessed as somatic; moderate impact.
- P17S (p.Pro17Ser), cosmic curated COSV58953
- N18D (p.Asn18Asp), TOPMed rs2079898641
- N18I (p.Asn18Ile), ExAC rs764202262, gnomAD rs764202262, CADD 23.30, PolyPhen-2 0.99
- N18K (p.Asn18Lys), TOPMed rs1351773687, gnomAD rs1351773687, CADD 22.00
- N19S (p.Asn19Ser), cosmic curated COSV10014
- N19D (p.Asn19Asp), gnomAD 19-40472676-A-G, MetaLR 0.40, MetaSVM -0.15
- N20I (p.Asn20Ile), 1000Genomes rs199950227, ExAC rs199950227, TOPMed rs199950227, gnomAD rs199950227, CADD 24.70, PolyPhen-2 0.99
- N20K (p.Asn20Lys), gnomAD rs1478794270, CADD 22.00, PolyPhen-2 0.95
- N20S (p.Asn20Ser), 1000Genomes rs199950227, ExAC rs199950227, TOPMed rs199950227, gnomAD rs199950227, CADD 22.80, PolyPhen-2 0.93
- N20del (p.Asn20del), gnomAD 19-40472672-TAAC-, CADD 16.70
- P21A (p.Pro21Ala), ExAC rs762129766, TOPMed rs762129766, gnomAD rs762129766, CADD 13.60, PolyPhen-2 0.02
- P21H (p.Pro21His), cosmic curated COSV10014
- P21L (p.Pro21Leu), rs765751602, ClinGen CA9445233, cosmic curated COSV58943, ClinVar RCV002786833, CADD 2.39, PolyPhen-2 0.00, Likely benign, Inborn genetic diseases
- P21R (p.Pro21Arg), ExAC rs765751602, gnomAD rs765751602, CADD 3.42, PolyPhen-2 0.23, Likely benign
- P21T (p.Pro21Thr), ExAC rs762129766, TOPMed rs762129766, gnomAD rs762129766, CADD 15.90, PolyPhen-2 0.06
- A22T (p.Ala22Thr), rs548831212, ClinGen CA9445234, ClinVar RCV003138805, ClinVar RCV005495530, CADD 0.18, PolyPhen-2 0.00, Uncertain significance, Neurodevelopmental disorder with hypotonia, neuropathy, and deafness; Inborn gen
- A22A (p.Ala22Ala), gnomAD 19-40472687-T-C, CADD 0.39
- A23T (p.Ala23Thr), ExAC rs754448570, gnomAD rs754448570, CADD 0.01, PolyPhen-2 0.00
- A23V (p.Ala23Val), TOPMed rs1383507907
- A23A (p.Ala23Ala), rs1392898952, gnomAD 19-40472690-C-T, CADD 3.13
- R24C (p.Arg24Cys), ExAC rs759994635, TOPMed rs759994635, gnomAD rs759994635, CADD 24.60, PolyPhen-2 0.65, Uncertain significance, Neurodevelopmental disorder with hypotonia, neuropathy, and deafness
- R24G (p.Arg24Gly), ExAC rs759994635, TOPMed rs759994635, gnomAD rs759994635
- R24H (p.Arg24His), rs146428235, ClinGen CA9445237, cosmic curated COSV58949, ClinVar RCV003727532, CADD 22.30, PolyPhen-2 0.00, Uncertain significance, not provided
- R24L (p.Arg24Leu), rs146428235, NCI-TCGA Cosmic COSV5894, ESP rs146428235, ExAC rs146428235, CADD 22.50, PolyPhen-2 0.25, Uncertain significance
- R24R (p.Arg24Arg), rs2079899176, gnomAD 19-40472693-C-T, CADD 9.43
- W25R (p.Trp25Arg), Ensembl rs1031817789
- W25* (p.Trp25Ter), gnomAD 19-40472696-G-A, CADD 41.00
- E26D (p.Glu26Asp), ExAC rs777536882, gnomAD rs777536882, CADD 14.20, PolyPhen-2 0.00
- E26K (p.Glu26Lys), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- E26V (p.Glu26Val), TOPMed rs2079899241, Uncertain significance, Inborn genetic diseases
- S27G (p.Ser27Gly), gnomAD rs1225471788
- S27R (p.Ser27Arg), gnomAD rs747825078, CADD 14.80, PolyPhen-2 0.96
- S27N (p.Ser27Asn), gnomAD 19-40472701-G-A, MetaLR 0.38, MetaSVM -0.48
- S27T (p.Ser27Thr), gnomAD 19-40472701-G-C, MetaLR 0.38, MetaSVM -0.53
- S27S (p.Ser27Ser), gnomAD 19-40472702-T-C, CADD 6.55
- P28L (p.Pro28Leu), rs1200592638, ClinGen CA405888254, ClinVar RCV002744933, ClinVar RCV004765747, CADD 23.00, PolyPhen-2 0.99, Uncertain significance, not provided; Inborn genetic diseases
- P28R (p.Pro28Arg), gnomAD rs1200592638, Uncertain significance
- P28S (p.Pro28Ser), ESP rs140771992, TOPMed rs140771992, gnomAD rs140771992, CADD 21.00, PolyPhen-2 0.98
- P28T (p.Pro28Thr), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- P28Q (p.Pro28Gln), gnomAD 19-40472704-C-A, MetaLR 0.50, MetaSVM -0.07
- P28P (p.Pro28Pro), gnomAD 19-40472705-G-T, CADD 1.44
- D29G (p.Asp29Gly), Ensembl rs2079899486, CADD 23.40, PolyPhen-2 0.32
- D29N (p.Asp29Asn), NCI-TCGA Cosmic COSV5894, cosmic curated COSV58947, Variant assessed as somatic; moderate impact.
- D29Y (p.Asp29Tyr), gnomAD 19-40472706-G-T, MetaLR 0.46, MetaSVM -0.12
- R30G (p.Arg30Gly), rs770792509, ClinGen CA405888280, ClinVar RCV003217136, CADD 23.10, PolyPhen-2 0.95, Uncertain significance, Inborn genetic diseases
- R30P (p.Arg30Pro), ExAC rs779001495, TOPMed rs779001495, gnomAD rs779001495, CADD 23.90, PolyPhen-2 0.98
- R30Q (p.Arg30Gln), ExAC rs779001495, TOPMed rs779001495, gnomAD rs779001495, CADD 23.40, PolyPhen-2 0.92
- R30W (p.Arg30Trp), rs770792509, NCI-TCGA Cosmic COSV5895, cosmic curated COSV58953, ExAC rs770792509, CADD 25.90, PolyPhen-2 0.98, Uncertain significance, Inborn genetic diseases
- R30R (p.Arg30Arg), rs770792509, gnomAD 19-40472709-C-A, CADD 12.00
- R30L (p.Arg30Leu), gnomAD 19-40472710-G-T, MetaLR 0.39, MetaSVM -0.51
- G31G (p.Gly31Gly), rs1453143359, gnomAD 19-40472714-C-A, CADD 11.00
- W32* (p.Trp32Ter), TOPMed rs1230516341, CADD 40.00
- W32C (p.Trp32Cys), TOPMed rs1230516341, CADD 28.70, PolyPhen-2 0.98, Uncertain significance, Inborn genetic diseases
- W32R (p.Trp32Arg), gnomAD rs1367287217, CADD 27.80
- E33K (p.Glu33Lys), TOPMed rs1307934970, CADD 24.00, PolyPhen-2 0.01, Uncertain significance, Inborn genetic diseases
- E33D (p.Glu33Asp), gnomAD 19-40472720-G-C, MetaLR 0.08, MetaSVM -0.93
- R34L (p.Arg34Leu), ExAC rs775690872, gnomAD rs775690872, CADD 24.80, PolyPhen-2 0.95
- R34Q (p.Arg34Gln), rs775690872, NCI-TCGA Cosmic COSV1001, cosmic curated COSV10015, ExAC rs775690872, CADD 24.70, PolyPhen-2 0.92, Variant assessed as somatic; moderate impact.
- R34W (p.Arg34Trp), rs372051643, ClinGen CA9445244, cosmic curated COSV58957, ClinVar RCV003189843, CADD 25.80, PolyPhen-2 0.98, Uncertain significance, Inborn genetic diseases
- E35G (p.Glu35Gly), Ensembl rs1568751642
- E35K (p.Glu35Lys), gnomAD rs1475569437, CADD 24.40, PolyPhen-2 0.43
- E35P (p.Glu35Pro), gnomAD 19-40472719-AGCGG, CADD 28.70
- Q36* (p.Gln36Ter), ESP rs375002828, ExAC rs375002828, TOPMed rs375002828, gnomAD rs375002828, CADD 39.00
- Q36E (p.Gln36Glu), ESP rs375002828, ExAC rs375002828, TOPMed rs375002828, gnomAD rs375002828, CADD 14.90, PolyPhen-2 0.01
- Q36K (p.Gln36Lys), ESP rs375002828, ExAC rs375002828, TOPMed rs375002828, gnomAD rs375002828, CADD 22.60, PolyPhen-2 0.00
- P37L (p.Pro37Leu), gnomAD rs1461355419, CADD 3.18, PolyPhen-2 0.04
- P37S (p.Pro37Ser), 1000Genomes rs541947221, ExAC rs541947221, gnomAD rs541947221, CADD 15.90, PolyPhen-2 0.06
- P37R (p.Pro37Arg), gnomAD 19-40472731-C-G, MetaLR 0.24, MetaSVM -0.86
- P37P (p.Pro37Pro), rs1055113527, gnomAD 19-40472732-G-A, CADD 0.10
- A38D (p.Ala38Asp), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- A38S (p.Ala38Ser), 1000Genomes rs73931308, ESP rs73931308, ExAC rs73931308, TOPMed rs73931308, CADD 10.20, PolyPhen-2 0.12, Benign
- A38T (p.Ala38Thr), rs73931308, ClinGen CA9445248, cosmic curated COSV58946, ClinVar RCV001710110, CADD 13.20, PolyPhen-2 0.06, Benign, Neurodevelopmental disorder with hypotonia, neuropathy, and deafness; not provid
- A38A (p.Ala38Ala), gnomAD 19-40472735-T-G, CADD 0.23
- A39S (p.Ala39Ser), rs201023290, ClinGen CA9445249, ClinVar RCV004457940, ESP rs201023290, CADD 5.35, PolyPhen-2 0.01, Uncertain significance, Inborn genetic diseases
- A39T (p.Ala39Thr), ESP rs201023290, ExAC rs201023290, TOPMed rs201023290, gnomAD rs201023290, CADD 8.64, PolyPhen-2 0.00, Uncertain significance
- A39V (p.Ala39Val), rs150447798, ClinGen CA9445251, cosmic curated COSV58953, ClinVar RCV000949841, CADD 13.50, PolyPhen-2 0.04, Likely benign, not provided
- A39A (p.Ala39Ala), rs371479246, gnomAD 19-40472738-G-A, CADD 0.58
- S40F (p.Ser40Phe), gnomAD rs1220738293, cosmic curated COSV10522, CADD 19.40, PolyPhen-2 0.03
- S40T (p.Ser40Thr), cosmic curated COSV99078
- T41A (p.Thr41Ala), 1000Genomes rs202134587, TOPMed rs202134587, gnomAD rs202134587, CADD 14.10, PolyPhen-2 0.00, Uncertain significance, Inborn genetic diseases
- T41I (p.Thr41Ile), ExAC rs763572029, TOPMed rs763572029, gnomAD rs763572029, CADD 14.40, PolyPhen-2 0.01
- T41T (p.Thr41Thr), rs766771630, gnomAD 19-40472744-C-T, CADD 0.10
- A42P (p.Ala42Pro), 1000Genomes rs187123741, ExAC rs187123741, TOPMed rs187123741, gnomAD rs187123741, CADD 18.70, PolyPhen-2 0.56
- A42S (p.Ala42Ser), 1000Genomes rs187123741, ExAC rs187123741, TOPMed rs187123741, gnomAD rs187123741, CADD 1.11, PolyPhen-2 0.12
- A42T (p.Ala42Thr), 1000Genomes rs187123741, ExAC rs187123741, TOPMed rs187123741, gnomAD rs187123741, CADD 7.52, PolyPhen-2 0.00
- A42V (p.Ala42Val), gnomAD 19-40472746-C-T, MetaLR 0.30, MetaSVM -0.39
- A42E (p.Ala42Glu), gnomAD 19-40472746-C-A, MetaLR 0.31, MetaSVM -0.44
- A42A (p.Ala42Ala), rs777582272, gnomAD 19-40472747-A-G, CADD 1.91
- A43V (p.Ala43Val), rs377262825, ClinGen CA9445257, ClinVar RCV002697540, ESP rs377262825, CADD 22.70, PolyPhen-2 0.77, Uncertain significance, Inborn genetic diseases
- A43T (p.Ala43Thr), gnomAD 19-40472748-G-A, MetaLR 0.33, MetaSVM -0.33
- A43A (p.Ala43Ala), rs777993962, gnomAD 19-40472750-G-A, CADD 0.12
- A44P (p.Ala44Pro), Ensembl rs2079900660, CADD 22.40, PolyPhen-2 0.01
- A44T (p.Ala44Thr), cosmic curated COSV99078, CADD 22.50, PolyPhen-2 0.43
- A44V (p.Ala44Val), gnomAD 19-40472752-C-T, MetaLR 0.64, MetaSVM 0.34
- A44A (p.Ala44Ala), gnomAD 19-40472753-C-G, CADD 5.83
- S45L (p.Ser45Leu), rs1488394403, TOPMed rs1488394403, gnomAD rs1488394403, CADD 24.50, PolyPhen-2 0.92, Variant assessed as somatic; moderate impact.
- S45W (p.Ser45Trp), TOPMed rs1488394403, gnomAD rs1488394403, CADD 24.60, PolyPhen-2 0.99
- S45R (p.Ser45Arg), gnomAD 19-40472751-GC-G, CADD 24.50
- S45S (p.Ser45Ser), gnomAD 19-40472756-G-T, CADD 0.68
- L46I (p.Leu46Ile), Ensembl rs2079900782, CADD 24.30, PolyPhen-2 0.93
- L46F (p.Leu46Phe), gnomAD 19-40472757-C-T, MetaLR 0.60, MetaSVM 0.12
- E48D (p.Glu48Asp), Ensembl rs1362654488
- E48Q (p.Glu48Gln), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- E48G (p.Glu48Gly), gnomAD 19-40472764-A-G, MetaLR 0.69, MetaSVM 0.51
- C49S (p.Cys49Ser), gnomAD 19-40472767-G-C, MetaLR 0.42, MetaSVM -0.13
- C49C (p.Cys49Cys), rs961672018, gnomAD 19-40472768-C-T, CADD 10.10
- S50P (p.Ser50Pro), gnomAD 19-40472769-T-C, MetaLR 0.40, MetaSVM -0.14
- S50Y (p.Ser50Tyr), gnomAD 19-40472770-C-A, MetaLR 0.46, MetaSVM -0.04
- S50S (p.Ser50Ser), gnomAD 19-40472771-C-A, CADD 9.38
- R51Q (p.Arg51Gln), gnomAD rs1474599629, CADD 29.90, PolyPhen-2 0.92
- R51W (p.Arg51Trp), Ensembl rs2079900977, CADD 24.30, PolyPhen-2 0.98
- R51R (p.Arg51Arg), gnomAD 19-40472772-C-A, CADD 8.41
- R51L (p.Arg51Leu), gnomAD 19-40472773-G-T, MetaLR 0.43, MetaSVM -0.15
- I52I (p.Ile52Ile), gnomAD 19-40472777-C-A, CADD 11.20
- K53R (p.Lys53Arg), rs966255951, ClinGen CA308414705, cosmic curated COSV10014, ClinVar RCV002767701, CADD 24.70, PolyPhen-2 0.93, Uncertain significance, Inborn genetic diseases
- K53Q (p.Lys53Gln), gnomAD 19-40472778-A-C, MetaLR 0.35, MetaSVM -0.34
- K53* (p.Lys53Ter), gnomAD 19-40472778-A-T, CADD 41.00
- K53T (p.Lys53Thr), gnomAD 19-40472779-A-C, MetaLR 0.35, MetaSVM -0.31
- K53N (p.Lys53Asn), gnomAD 19-40472780-G-T, MetaLR 0.45, MetaSVM 0.00
- A54T (p.Ala54Thr), rs1166037726, ClinGen CA405888442, ClinVar RCV002469524, TOPMed rs1166037726, CADD 27.20, PolyPhen-2 0.97, Uncertain significance, not provided
- A54S (p.Ala54Ser), gnomAD 19-40472781-G-T, MetaLR 0.36, MetaSVM -0.41
- A54D (p.Ala54Asp), gnomAD 19-40472782-C-A, MetaLR 0.38, MetaSVM -0.35
- A54A (p.Ala54Ala), gnomAD 19-40472783-C-T, CADD 12.00
- L55W (p.Leu55Trp), gnomAD 19-40472785-T-G, MetaLR 0.51, MetaSVM 0.17
- L55F (p.Leu55Phe), gnomAD 19-40472786-G-C, MetaLR 0.43, MetaSVM -0.18
- A56V (p.Ala56Val), gnomAD 19-40472788-C-T, MetaLR 0.35, MetaSVM -0.29
- A56E (p.Ala56Glu), gnomAD 19-40472788-C-A, MetaLR 0.26, MetaSVM -0.66
- A56A (p.Ala56Ala), gnomAD 19-40472789-A-T, CADD 23.10
- D57L (p.Asp57Leu), gnomAD 19-40472788-C-CTC, CADD 28.30
- D57Y (p.Asp57Tyr), gnomAD 19-40472790-G-T, MetaLR 0.56, MetaSVM 0.28
- D57N (p.Asp57Asn), gnomAD 19-40472790-G-A, MetaLR 0.43, MetaSVM -0.14
- D57G (p.Asp57Gly), gnomAD 19-40487697-A-G, MetaLR 0.40, MetaSVM -0.16
- D57D (p.Asp57Asp), rs754902114, gnomAD 19-40487698-T-C, CADD 16.00
- E58D (p.Glu58Asp), NCI-TCGA TCGA novel, cosmic curated COSV10886, CADD 22.90, PolyPhen-2 0.82, Variant assessed as somatic; moderate impact.
Public SPTBN4 analysis runs
- SPTBN4 analysis run — SPTBN4 (3,489 variants) — completed 2026-08-20